The American Gastroenterological Association has updated guidance for the treatment of ulcerative colitis to recommend using higher efficacy drugs in earlier stages of treatment, Medscape Medical News ...
AGA living guideline recommends patients start advanced therapies early in their disease course rather than gradual step-up treatment approach. “Since the first biologic treatment for ulcerative ...
Credit: Getty Images What have we learned in recent years about the safety and efficacy of different biologics for the treatment of ulcerative colitis? Ulcerative colitis (UC) is a condition with a ...
An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...
How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...
More than a quarter of patients with ulcerative colitis do not receive prior advanced therapy before initiating mirikizumab, ...
Thetis Pharmaceuticals, LLC ("Thetis"), a clinical-stage company developing TP-317, a first-in-class, oral BLT1 agonist for inflammatory bowel disease (IBD) and cancer, today announced the appointment ...
Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...
A 52-week phase 3 clinical trial of Skyrizi, or risankizumab — a drug initially approved to treat Crohn’s disease, psoriatic arthritis and psoriasis — was shown to also achieve clinical remission in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results